Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGS742 in mild to moderate Alzheimer's disease
NCT00093951Phase 2Completed
- Sponsor
- Saegis Pharmaceuticals
- Start
- Apr 2004
- Primary completion
- Sep 2007
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing SGS742 with Placebo (2 arms). Primary endpoint: Effect of SGS742 on memory and cognition at 3 months. Started Apr 2004; status: completed.
02
Drugs
SGS-742
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00093951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093951.